JMP Securities downgraded Agilon Health from Mkt Outperform to Mkt Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/11/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 11/8/2024 | Outperform → Mkt Perform | William Blair | |
| 10/30/2024 | $7.00 → $2.50 | Neutral → Sell | Citigroup |
| 10/2/2024 | $3.00 | Buy → Underperform | BofA Securities |
| 5/30/2024 | $6.00 | Neutral | Robert W. Baird |
| 4/22/2024 | $6.00 | Neutral | Citigroup |
| 3/6/2024 | $5.00 | Underweight | Barclays |
| 2/26/2024 | $25.00 → $6.50 | Buy → Hold | Jefferies |
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 50 points on Thursday. Shares of Leslie’s, Inc. (NASDAQ:LESL) fell sharply in today's pre-market trading after the company issued preliminary third-quarter financial results below estimates and cut its FY24 guidance. After the market close on Wednesday, Leslie's announced it now expects third-quarter revenue of approximately $570 million versus estimates of $615.407 million. The pool supply company anticipates third-quarter adjusted earnings of 32 cents to 33 cents per share versus Benzinga Pro estimates of 42 cents per share. Leslie's also cut its full-year 2024 revenue guidance from a range of $1.14
Analysts' ratings for Agilon Health (NYSE:AGL) over the last quarter vary from bullish to bearish, as provided by 6 analysts. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 6 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 2 0 0 3M Ago 0 0 3 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $6.48, with a high estimate of $7.00 and a low estimate of $6.00. Highlighting a 5.4% decrease, the current average has fallen from the pr
Evercore ISI Group analyst Elizabeth Anderson maintains Agilon Health (NYSE:AGL) with a In-Line and raises the price target from $5.5 to $7.
8-K - agilon health, inc. (0001831097) (Filer)
10-Q - agilon health, inc. (0001831097) (Filer)
8-K - agilon health, inc. (0001831097) (Filer)
4 - agilon health, inc. (0001831097) (Issuer)
4 - agilon health, inc. (0001831097) (Issuer)
4 - agilon health, inc. (0001831097) (Issuer)
SC 13G/A - agilon health, inc. (0001831097) (Subject)
SC 13G/A - agilon health, inc. (0001831097) (Subject)
SC 13G/A - agilon health, inc. (0001831097) (Subject)
JMP Securities downgraded Agilon Health from Mkt Outperform to Mkt Perform
William Blair downgraded Agilon Health from Outperform to Mkt Perform
Citigroup downgraded Agilon Health from Neutral to Sell and set a new price target of $2.50 from $7.00 previously
Revenue increased 28% to $1.45 billion, Medicare Advantage membership increased 37% to 525,000, and total members on the agilon platform grew 39% to 657,000 Third quarter results were affected by lower-than-expected 2024 risk adjustment, negative prior year development mainly from risk adjustment and Part D, and higher current year medical expenses Adjusted full year guidance reflects Q3 results and updated Q4 cost trends agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, today announced results for the third quarter ended September 30, 2024. "Our full-risk model enables primary care physicians to deliver high-quality c
agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced that it will release its financial results for the third quarter 2024 after the market closes on Thursday, November 7, 2024, and host a conference call at 4:30 PM Eastern Time the same day to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 520026. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of
Revenue increased 39% to $1.5 billion, Medicare Advantage membership increased 38% to 513,000, and total members on the agilon platform grew 40% to 645,000 Executing targeted action plan and prioritizing profitability First half results reflect retroactive membership adjustments to January 1, 2024 related to agilon's termination of select contracts Maintains 2024 Medical Margin and Adjusted EBITDA Guidance agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced results for the second quarter ended June 30, 2024. "Our second quarter results were in-line with our guidance, and we are maintaining medical margin
Dr. Rao to Continue to Lead Clinical Strategy and Drive Physician Network Performance Alongside agilon's Chief Clinical Officer Kevin Spencer, M.D. agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that after a comprehensive search Karthik Rao, M.D., who has served as agilon's interim chief medical officer (CMO) since February 2024, has been appointed to the permanent CMO role, effective immediately. He previously served as senior medical director and vice president, network performance, at the company. Prior to joining agilon in 2022, Dr. Rao held several roles in value-based care, including nearly a d
agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that Jeff Schwaneke, an experienced finance, operational and managed care executive and director on agilon's board, will join the Company as chief financial officer and executive vice president effective July 1, 2024. He will be a member of agilon's Executive Leadership team reporting to chief executive officer (CEO), Steve Sell. Schwaneke succeeds Timothy Bensley, who announced his retirement from agilon in early 2024. Bensley has agreed to stay on through a transition period. Schwaneke was most recently executive vice president, Health Care Enterprises,
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, May 13, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises agilon health, inc. (NYSE:AGL) investors that a lawsuit was filed on behalf of investors that purchased agilon securities between April 15, 2021 and February 27, 2024, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to
4 - agilon health, inc. (0001831097) (Issuer)
4 - agilon health, inc. (0001831097) (Issuer)
4 - agilon health, inc. (0001831097) (Issuer)
Revenue increased 28% to $1.45 billion, Medicare Advantage membership increased 37% to 525,000, and total members on the agilon platform grew 39% to 657,000 Third quarter results were affected by lower-than-expected 2024 risk adjustment, negative prior year development mainly from risk adjustment and Part D, and higher current year medical expenses Adjusted full year guidance reflects Q3 results and updated Q4 cost trends agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, today announced results for the third quarter ended September 30, 2024. "Our full-risk model enables primary care physicians to deliver high-quality c
agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced that it will release its financial results for the third quarter 2024 after the market closes on Thursday, November 7, 2024, and host a conference call at 4:30 PM Eastern Time the same day to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 520026. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of
Revenue increased 39% to $1.5 billion, Medicare Advantage membership increased 38% to 513,000, and total members on the agilon platform grew 40% to 645,000 Executing targeted action plan and prioritizing profitability First half results reflect retroactive membership adjustments to January 1, 2024 related to agilon's termination of select contracts Maintains 2024 Medical Margin and Adjusted EBITDA Guidance agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced results for the second quarter ended June 30, 2024. "Our second quarter results were in-line with our guidance, and we are maintaining medical margin